Social media users within Parkinson’s community and beyond, led by BBC journalist Jeremy Vine, have reacted to the death of The Cure Parkinson’s Trust co-founder Tom Isaacs
Emotional outpourings from social media users and Parkinson’s organisations have been published around the world in response to the news that Tom Isaacs, co-founder of The Cure Parkinson’s Trust, died on Wednesday 31 May.
Not long after the news broke, members of Parkinson’s community took to Twitter to pay their respects.
BBC Radio 2 journalist Jeremy Vine led the way, hailing the significance of the “beautiful” Parkinson’s campaigner.
Ann Hanley, founder of the Ann Hanley Parkinson’s Research Fund, revealed that it was Tom Isaacs who inspired her to start her own Parkinson’s organisation.
Ann said: “I am so devastated by the news. Tom was my friend and inspiration. He inspired me to start my own foundation.
“He was a giant among men, a visionary, a dreamer, a man who never gave up, who never quit. He made me laugh and was ever the optimist. I thank God for the privilege of knowing Tom and though saddened by his early demise, he will forever be with me in my thoughts and prayers as I continue to dedicate my life to our common cause.”
The British and Irish Lions, who hosted a charity dinner for The Cure Parkinson’s Trust in April, passed on a message of support.
The British & Irish Lions are very sad to hear the passing of the inspirational Tom Isaacs. https://t.co/e3acUAhKo7
We interviewed Tom to find out more about how the ‘Cure3’ exhibition, a contemporary art exhibition and auction – which included work from Damien Hirst, Grayson Perry and Sarah Lucas – raised money for The Cure Parkinson’s Trust, January 2017.
Michael J Fox hopes Trump government will continue support for Parkinson’s research
Will the Trump administration support Parkinson’s research?
5 months ago
35 new Parkinson’s drug trials launched in last year
Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.